Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 859 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR 27-Year-Old Diagnosed with Cancer at 20 Weeks Pregnant Gives Birth Amid... July 3, 2020 Keeping A Jasmine Plant In Your Room Reduces Anxiety, Panic Attacks... April 12, 2019 Tarlatamab Shows Promise in Patients with Previously Treated Small-Cell Lung Cancer October 31, 2023 First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable... July 5, 2021 Load more HOT NEWS Finally Pregnant After Struggling With Infertility For Years, She Was Diagnosed... New drug available for rare thyroid cancer on NHS in England Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours